We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Neuro-oncology
MedXY News
EnglishTag

Neuro-oncology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Rethinking Meningioma Management: Incidence Surge Amid Stable Treatment and Extensive Imaging Surveillance
Neurologyimaging surveillancemeningioma

Rethinking Meningioma Management: Incidence Surge Amid Stable Treatment and Extensive Imaging Surveillance

By MedXY|Aug 21, 2026

Between 2010 and 2023 in Denmark, meningioma incidence doubled while treatment rates remained steady. Extensive follow-up imaging was common but rarely altered management, highlighting opportunities for risk-adapted surveillance protocols.

AI Assistant Achieves High Accuracy in Molecular-Based CNS Tumor Classification: A Multi-Institutional Validation
AIartificial intelligencedigital health
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

AI Assistant Achieves High Accuracy in Molecular-Based CNS Tumor Classification: A Multi-Institutional Validation

By MedXY|Feb 18, 2026

This multi-institutional study validates Neuropath-AI, a deep-learning system that predicts CNS tumor types by inferring molecular features from histopathology slides. Achieving 80% top-1 accuracy in high-confidence samples, the model offer

Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit
NeurologygliomaIDH mutation

Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit

By MedXY|Jan 5, 2026

The final analysis of the EORTC CATNON trial reveals that 12 cycles of adjuvant temozolomide significantly extend overall survival to 12.5 years in IDH-mutated anaplastic astrocytoma, whereas concurrent temozolomide provides no added clinic

GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
newsNeuro-oncology

GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma

By MedXY|Dec 23, 2025

The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent gliobl

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities